JP2006117697A5 - - Google Patents

Download PDF

Info

Publication number
JP2006117697A5
JP2006117697A5 JP2006002633A JP2006002633A JP2006117697A5 JP 2006117697 A5 JP2006117697 A5 JP 2006117697A5 JP 2006002633 A JP2006002633 A JP 2006002633A JP 2006002633 A JP2006002633 A JP 2006002633A JP 2006117697 A5 JP2006117697 A5 JP 2006117697A5
Authority
JP
Japan
Prior art keywords
leu
peptide
amino acids
peptide according
hydrophobic amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006002633A
Other languages
English (en)
Japanese (ja)
Other versions
JP4522367B2 (ja
JP2006117697A (ja
Filing date
Publication date
Priority claimed from AUPN0590A external-priority patent/AUPN059095A0/en
Priority claimed from AUPN0589A external-priority patent/AUPN058995A0/en
Application filed filed Critical
Publication of JP2006117697A publication Critical patent/JP2006117697A/ja
Publication of JP2006117697A5 publication Critical patent/JP2006117697A5/ja
Application granted granted Critical
Publication of JP4522367B2 publication Critical patent/JP4522367B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006002633A 1995-01-16 2006-01-10 新規ペプチド Expired - Fee Related JP4522367B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN0590A AUPN059095A0 (en) 1995-01-16 1995-01-16 Novel lipopeptide
AUPN0589A AUPN058995A0 (en) 1995-01-16 1995-01-16 Novel peptide

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005034053A Division JP2005145985A (ja) 1995-01-16 2005-02-10 新規ペプチド

Publications (3)

Publication Number Publication Date
JP2006117697A JP2006117697A (ja) 2006-05-11
JP2006117697A5 true JP2006117697A5 (enExample) 2006-11-09
JP4522367B2 JP4522367B2 (ja) 2010-08-11

Family

ID=25644844

Family Applications (3)

Application Number Title Priority Date Filing Date
JP52191796A Expired - Fee Related JP3665342B2 (ja) 1995-01-16 1996-01-16 新規ペプチド
JP2005034053A Pending JP2005145985A (ja) 1995-01-16 2005-02-10 新規ペプチド
JP2006002633A Expired - Fee Related JP4522367B2 (ja) 1995-01-16 2006-01-10 新規ペプチド

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP52191796A Expired - Fee Related JP3665342B2 (ja) 1995-01-16 1996-01-16 新規ペプチド
JP2005034053A Pending JP2005145985A (ja) 1995-01-16 2005-02-10 新規ペプチド

Country Status (8)

Country Link
US (1) US6057294A (enExample)
EP (1) EP0804469B1 (enExample)
JP (3) JP3665342B2 (enExample)
AU (1) AU694602B2 (enExample)
CA (1) CA2210812C (enExample)
DE (1) DE69617396T2 (enExample)
ES (1) ES2168456T3 (enExample)
WO (1) WO1996022306A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057294A (en) * 1995-01-16 2000-05-02 Northern Sydney Area Health Service Of Pacific Highway Peptide
AU2020497A (en) * 1996-03-27 1997-10-17 Susan R. George Receptor and transporter antagonists
US20050070478A1 (en) * 1996-06-11 2005-03-31 Northern Sydney Area Health Services T cell antigen receptor peptides
AU739130B2 (en) * 1996-06-11 2001-10-04 Northern Sydney And Central Coast Area Health Service T cell antigen receptor peptides
TR199902786T2 (xx) * 1997-04-11 2000-06-21 Sangstat Medical Corporation Ba����kl�k sistemi faaliyetinin d�zene sokulmas� ve iltihaplanman�n durdurulmas� i�in lipofilik peptidlerin h�cre yap�s�n�n d�zene konulmas�.
US6696545B1 (en) 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
JP2003534287A (ja) * 2000-05-19 2003-11-18 ユニバーシティ・オブ・メリーランド, ボルティモア 糖尿病発症を予防または遅延させるためのゾヌリンのペプチドアンタゴニストの使用方法
US7094413B2 (en) 2002-01-24 2006-08-22 Sangstat Medical Corporation Combined therapy for treatment of HIV infection
US7795223B2 (en) * 2004-05-27 2010-09-14 Novozymes Biopharma Au Ltd. Treatment of inflammatory airway disease
US20090275503A1 (en) * 2005-09-22 2009-11-05 Yeda Research And Developent Co., Ltd. At The Weizman Institute Of Science Diastereomeric peptides for modulating t cell immunity
EP1870420A1 (en) * 2006-06-23 2007-12-26 Max-Delbrück-Centrum Für Molekulare Medizin Peptides regulating the surface expression of the T cell receptor
AU2009317889A1 (en) * 2008-11-24 2011-07-07 Sydney West Area Health Service Cyclic peptides and uses thereof
US10138276B2 (en) 2009-09-30 2018-11-27 Signablok, Inc. Inhibition of TCR signaling with peptide variants
WO2011047097A2 (en) * 2009-10-13 2011-04-21 Sigalov Alexander B Inhibition of trem receptor signaling with peptide variants
JP7249287B2 (ja) 2017-03-31 2023-03-30 ザ・ボード・オブ・トラスティーズ・オブ・ザ・リーランド・スタンフォード・ジュニア・ユニバーシティ T細胞受容体シグナル伝達を阻害または調節することによって、t細胞枯渇を処置する方法
EP3836951A1 (en) 2018-08-13 2021-06-23 Signablok, Inc. Peptides and compositions for targeted treatment and imaging

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888512A (en) * 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
US5223485A (en) * 1989-01-31 1993-06-29 Abbott Laboratories Anaphylatoxin-receptor ligands
EP0456758A4 (en) * 1989-01-31 1992-07-08 Abbott Laboratories Anaphylatoxin-receptor ligands
KR0185373B1 (ko) * 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
WO1991019797A1 (en) * 1990-06-15 1991-12-26 New York University Heterohybridomas producing human monoclonal antibodies to hiv-1
US5387671A (en) * 1990-12-27 1995-02-07 Abbott Laboratories Hexa- and heptapeptide anaphylatoxin-receptor ligands
WO1994020127A1 (en) * 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
ES2236703T3 (es) * 1994-01-14 2005-07-16 Matthias Dr Med Rath Uso de metodos para identificar oligopeptidos de señal hidrofilos.
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
AU2238395A (en) * 1994-04-01 1995-10-23 Immulogic Pharmaceutical Corporation Haptenated peptides and uses thereof
US6057294A (en) * 1995-01-16 2000-05-02 Northern Sydney Area Health Service Of Pacific Highway Peptide
US5753625A (en) * 1995-05-12 1998-05-19 Sangstat Medical Corporation Treatment for inhibiting the progression of autoimmune disease

Similar Documents

Publication Publication Date Title
JP2006117697A5 (enExample)
JPWO2020209285A5 (enExample)
JP2012525844A5 (enExample)
JP2009504157A5 (enExample)
MX2007013031A (es) Agentes terapeuticos de peptidos de toxina.
JP2013537907A5 (enExample)
JP2010515686A5 (enExample)
JP2008541759A5 (enExample)
JP2013507439A5 (enExample)
JP2006506942A5 (enExample)
TW200833840A (en) Toxin peptide therapeutic agents
JP2009537143A5 (enExample)
JP2007530577A5 (enExample)
JP2008529500A5 (enExample)
JP2018515101A5 (enExample)
JP2011528332A5 (enExample)
MX2013011674A (es) Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
JP2009511579A5 (enExample)
JP2011511753A5 (enExample)
JP2014527040A5 (enExample)
JP2014532722A5 (enExample)
RU2011121971A (ru) Пептиды-производные ил-4 для модуляции хронического воспалительного ответа и лечения аутоиммунных заболеваний
RU2014105513A (ru) Противофиброзные пептиды и их применение в способах лечения заболеваний и расстройств, характеризующихся фиброзом
JP2014529399A5 (enExample)
JP2004531242A5 (enExample)